Apoptosis or programmed cell death is a form of cell death in which the cell participiates in its own demise (1, 2). Apoptosis has traditionally been contrasted to necrotic or accidental cell death in which the cell dies as a result of overwhelming external physical or toxic injury (2). The term apoptosis was coined originally to define a morphological event in which the nucleus and cytoplasm undergo condensation and fragmentation into discrete membrane-bound bodies (1, 2) . This definition expanded later to include the degradation of chromosomal DNA into oligonucleosomal-sized fragments of 180-200 by multiples (3). Subsequent studies have shown that prior to or in place of oligonucleosomal fragmentation, the DNA is cleaved into 300 kb and 50 kb fragments (4). More recently, apoptosis triggered by many different stimuli has been shown to result in the cleavage of intracellular proteins by cysteine proteases at specific sites following aspartate residues (5-8). This was originally recognized when it was shown that the nuclear protein poly (ADPribose) polymerase (PARP) was cleaved at a specific site following exposure to various chemotherapeutic agents (5). It has since been shown that several other nuclear and cytoplasmic proteins are cleaved by cysteine proteases during apoptosis (6) (7) (8) . Of interest, all of the known cysteine proteases are expressed in a pro-enzyme form and are activated by cleavage at specific Asp-X sites (6-8). The outcome is the activation of a protease cascade which culminates in enzymatic degradation of the cell.
The role that apoptosis plays in pathophysiological processes has been extensively reviewed in recent years and the interested reader is referred to several excellent articles (9) (10) (11) (12) . Briefly, the areas in which apoptosis plays an important role can be divided as follows : 1) during embryological and fetal development e.g. cavitation of the embryo and limb bud development (2, 13) ; 2) in normal homeostasis, e.g. turnover of intestinal epithelial cells (1, 2) ; 3) in disease states.
In the case of diseases, apoptosis may be down-modulated resulting in neoplasia, e.g. follicular lymphoma as a result of upregulation of BcI-2 or there may be increased apoptosis as in the case of several neurodegenerative disorders (9).
Significance of Endothelial Cell Apoptosis
Regulation of endothelial cell (EC) death/survival has been suggested to have a role in vascular development and angiogenesis, and in the pathophysiology of wound healing, inflammation and radiation injury (14) (15) (16) (17) (18) (19) . Vascular cell death has also been associated with atherosclerosis (20-24). Studies using human tissue have reported vastly different numbers of apoptotic cells in atherosclerotic lesions. Where increased numbers of dead cells have been reported these have mainly been localized to the neointima (20) (21) (22) . Apoptotic cells are more frequently detected in restenotic lesions than in primary lesions (22) . Although most studies suggest that the majority of dying cells are smooth muscle cells or macrophages, a study of transplant coronary artery disease reports large numbers of apoptotic EC (24). In contrast to the above studies, examination of atherosclerotic plaques of cholesterol-fed rabbits shows very low numbers of apoptotic cells (23). The discrepant findings reported in these studies could result from normal physiological variability. Alternatively, differences in the model of atherosclerosis studied, the species differences, the stage of the lesions, and method used to quantify dead cells could all play a major role in explaining the differences. As can be seen from these studies, much remains to be learned about the role of apoptosis in atherosclerosis.
Recently, we have shown that apoptotic EC in culture become procoagulant (Bombeli et al, manuscript submitted) and also increase their adhesivity for leukocytes (Schwartz et al, manuscript in preparation) .
We speculate that both these functional changes may contribute to atherosclerosis.
The latter by recruiting monocytes to the site of EC apoptosis, hence initiating and/or propagating lesion formation, and the former may play a role in thrombotic events associated with atherosclerotic lesions.
Mechanism of Tumor Necrosis Factor-a (TNF)-mediated Apoptosis
Propagation of the death signal has been intensively studied for two membrane receptors, Fas (APO1) and TNFreceptor 1 (TNF-R1) (7). Engagement of the TNF-R1 by trimeric TNF results in recruitment of adaptor proteins to the cell membrane.
The adaptor protein, TRADD, associates with TNF-R1 and another protein, FADD/Mortl, associates with TRADD (7). Both these interactions occur through a conserved amino acid motif designated the death domain (7). FADD also associates with a novel protein, MACH/FLICE, via a second domain termed the death effector domain (7, 25, 26 The BcI-2 Family of Anti-apoptotic Proteins Several types of proteins have been shown to contribute to cell survival including the BcI-2 family, anti-oxidants, serine-protease inhibitors, the zinc-finger protein, A20, and more recently the inhibitor of apoptosis protein (IAP) family of mammalian proteins related to the baculovirus IAP (32, (34) (35) (36) .
The best studied group of cell survival molecules is the BcI-2 family, defined originally by two conserved motifs, BH1 and BH2, and now demonstrated to have at least four functional domains (34, 37-39). As well, most members of the family have a transmembrane domain which anchors the protein to intracellular membranes such as the outer membrane of mitochondria (34, 39). The mechanism by which BcI-2 functions remains obscure, but BcI-2 has been shown to block the end result of oxidant stress such as lipid peroxidation and also to prevent the activation of the death protdases (40-42). The mammalian members of the BcI-2 family include : BcI-XL, McI-1, A1, BcI-XS, Bax, Bak, Bik and BRAG-1 (34). These proteins form homo-and heterodimers with other members of the family which may be important for function (34). The BH1 and BH2 domains of BcI-2 are necessary for heterodimerization with Bax (34). BcI-2, BcI-XL, McI-1 and A1 have been shown to have a protective function in many, but not all, models of apoptosis (17, 34). BcI-XS blocks the Components of the death pathway are constitutively expressed, while the survival pathway comprises both inducible and constitutive proteins (X indicates inhibition). protective effect of Bcl-XL and Bcl-2 (34).
The function of Bax is somewhat enigmatic. In some circumstances Bax enhances apoptosis, but on the other hand, there is evidence to suggest that heterodimerization with Bcl-2 and Bcl-XL is required for these proteins to block apoptosis (43, 44). However, another study concludes that Bax is not required for Bcl-XL function (45). Targeted disruption of Bax results in a mouse that is viable and shows decreased lymphoid apoptosis but increased apoptosis in the testis (46). It is felt that the balance between homo-and heterodimerization of these family members may be the rheostat that regulates cell death (34).
Another cytoprotective molecule that is not a member of the Bcl-2 family is the zinc-finger protein, A20 (32). Again the mode of function of this protein is unclear.
It has been shown that A20 is recruited to the TNF-R2 by the adaptor molecules called TRAFs (47). Subsequent to recruitment to the plasma membrane, A20 blocks signalling mediated by NFkB (47, 48) . A20 is inducible by inflammatory cytokines and protects against the toxicity of TNF (32). However, A20 does not protect against all triggers of apoptosis (48).
Prevention of Apoptosis in Endothelial Cells
In , it is not possible to make a definitive conclusion on the relative importance of this finding. The conflicting results of the studies described need to be reconciled and may relate to the different cross-linking antibodies used in the studies (51, 52). The role of various extracellular matrix proteins in EC survival is also an area of investigation in which several laboratories have become interested.
Araki and colleagues have shown that serum-and growth factor-deprivation leads to human umbilical vein EC apoptosis which can be inhibited by basic fibroblast growth factor (bFGF) (53). We have used this model to show that the bFGF can inhibit apoptosis independently of its mitogenic capability (Karsan et al, manuscript submitted). We have shown further that bFGF upregulates Bcl-2 in human umbilical vein EC. Although, Bcl-XL, Mcl-1 and Bax are also expressed in HUVEC, these BcI-2 family members are not regulated by bFGF. Upregulation of Bcl-2 occurs at later time-points, however, bFGF provides a protective effect as early as three hours following serum-and growth factor-deprivation (Karsan et al, manuscript submitted). Thus, it remains to be seen how bFGF mediates its early survival effects.
We speculate, based on the ability of bFGF to modulate the levels of EC integrins, that bFGF may provide early protection by maintaining EC adhesion to extracellular matrix (54). We have provided a possible schema of the role of adhesion and growth factors in maintaining EC survival in Fig . 2 
